ClinicalTrials.gg
CompletedNCT06851858ARAYUpdated Sep 24, 2026

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

A Phase 2 interventional study of AZD6234 and Placebo to match in Endocrinology, Diabetes, Type II and Obesity, sponsored by AstraZeneca. Completed at 18 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Enrollment
177th of 280
69 · median 155
Started
2025
with 5 others
Phase 2
41 of 345
none open now
Registered
325th of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 177th largest by enrollment of the 280 interventional ones that give a count, is one of 6 that started in 2025, is one of 41 in phase 2, and was the 325th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.

Read the detailed description

This is a Phase II, randomised, parallel-group, double-blind, placebo-controlled, multi-centre study to assess the efficacy, safety, and tolerability of AZD6234 compared with placebo, given once weekly as a subcutaneous (SC) injection, in adults living with overweight or obesity and type 2 diabetes who are on a stable dose of GLP-1 RA. The study is being conducted across sites in the USA to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy. A total of 64 Participants, aged 18-75 with a BMI ≥ 27 kg/m², will be randomized to receive weekly subcutaneous injections of either AZD6234 or a placebo, alongside their current GLP-1 RA medication. The study involves a screening period and a treatment and follow-up period.

03

Conditions studied

  • Endocrinology
  • Diabetes, Type II
  • Obesity

Keywords

  • Diabetes, Type II
  • Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18 to 75 years old at the time of signing the .
  2. Diagnosed with type 2 diabetes ≥ 180 days before screening.
  3. value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol).
  4. On a stable maintenance dose of an injectable GLP-1 RA.
  5. At Screening, have a ≥ 27 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA).
  2. Self-reported weight change of > 5 % in the 3 months prior to screening.
  3. Diabetes mellitus that is not clearly type 2 diabetes.
  4. Use of insulin therapy for T2DM
  5. Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
  6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis)

8. Impaired renal function defined as ≤ 45 mL/minute/1.73m2 at screening

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    AZD6234

    Weekly SC injections of AZD6234

    Drug: AZD6234

  • Placebo comparator
    Placebo for AZD6234

    Weekly SC injections of matching placebo

    Drug: Placebo to match

Interventions

  • Weekly SC injections of AZD6234

  • DrugPlacebo to match

    Weekly SC injections of matching placebo

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline at Study Week 26

    To determine whether treatment with AZD6234 is superior to placebo for weight loss at Study Week 26

    Time frame: From baseline to week 26

  2. Weight loss ≥ 5% from baseline at Study Week 26

    To assess the effect of AZD6234 versus placebo on the proportion of participants with weight loss ≥ 5% from baseline at Study Week 26

    Time frame: From baseline to week 26

Secondary outcomes

  1. Weight loss ≥ 10% from baseline at Study Week 26

    To assess the effect of AZD6234 versus placebo on the proportion of participants with weight loss ≥ 10% from baseline at Study Week 26

    Time frame: From baseline to week 26

  2. Absolute change in body weight (kg) from baseline at Study Week 26

    To determine whether AZD6234 is superior to placebo for absolute weight reduction (kg) at Study Week 26

    Time frame: From baseline to week 26

  3. Change in HbA1c from baseline at Study Week 26.

    To assess the effect of AZD6234 versus placebo on glycaemic control at Study week 26

    Time frame: From baseline to week 26

  4. AZD6234 plasma concentrations

    To characterise the PK of AZD6234

    Time frame: From baseline to week 26

  5. Change in serum glucose from baseline at Study Week 26.

    To assess the effect of AZD6234 versus placebo on glycaemic control at Study week 26

    Time frame: From baseline to week 26

07

Study locations

18 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Doral, Florida 33166, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Canton, Georgia 30114, United States
  • Research Site
    Fayetteville, Georgia 30214, United States
  • Research Site
    Chicago, Illinois 60640, United States
  • Research Site
    Oak Brook, Illinois 60523, United States
  • Research Site
    Newton, Kansas 67114, United States
  • Research Site
    Lexington, Kentucky 40509, United States
  • Research Site
    Kansas City, Missouri 64114, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 14 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 14 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 28, 2025
StartActual
Mar 12, 2025
Primary completionActual
May 26, 2026
CompletionActual
May 26, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06851858
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Mar 12, 2025
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6234

Start the discussion